Arihant Capital Markets (‘Manager to the Offer’) on behalf of Ipca Laboratories Limited (‘Acquirer’) has informed this Corrigendum to the DPS in respect of the Open Offer to the Equity Shareholders of Krebs Biochemicals and Industries (‘Target Company’) pursuant to and in compliance with Regulation 3(1) and (4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto (‘SEBI SAST Regulations’). This Corrigendum is being issued pursuant to changes / amendments advised by SEBI vide their letter dated October 21, 2015 and should be read in conjunction with the DPS published on February 24, 2015 in publications. The terms used in this Corrigendum to the DPS have the same meaning assigned to them in the DPS issued earlier, unless otherwise specified.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Motilal Oswal Fin | 805.00 |
| Angel One | 318.20 |
| IIFL Capital Service | 310.45 |
| Nuvama Wealth | 1377.30 |
| Share India Sec. | 144.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: